Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1199 results
April 2016
-
Media ReleaseNovartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever SyndromesSubject to approvals, Ilaris® will likely be first FDA-approved treatment for TRAPS and HIDS/MKD, and an important alternative treatment for patients with FMF Designations support potential…
-
Media ReleaseNovartis erzielt im ersten Quartal trotz Verlust der Exklusivrechte an Gleevec solide Ergebnisse und investiert in Neueinführungen zugunsten langfristigen WachstumsDer Nettoumsatz steigt um 1% (kWk[1]), da die Wachstumsprodukte die Einbussen bei Gleevec kompensieren Die Wachstumsprodukte[2] steigern den Umsatz um 24% (USD) auf USD 3,9 Milliarden bzw. 34%…
-
Media ReleaseNovartis a enregistré un premier trimestre solide, malgré la perte d'exclusivité de Gleevec, et investi dans de nouveaux lancements pour soutenir la croissance à long termeChiffre d'affaires net en hausse de 1% (tcc[1]), les produits de croissance ayant compensé l'impact du générique de Gleevec Les produits de croissance[2] ont progressé de 24% (en USD) à USD 3,9…
-
Media ReleaseNovartis delivered solid Q1 despite Gleevec loss of exclusivity; investing behind new launches for long-term growthNet sales up 1% (cc[1]), as Growth Products offset Gleevec impact Growth Products[2] grew 24% (USD) to USD 3.9 billion, or 34% of Group net sales Cosentyx (USD 176 million) continues to grow…
-
Media ReleaseNovartis drug Afinitor® significantly reduces seizures in Phase III study of patients with tuberous sclerosis complexEverolimus is the first adjunctive therapy shown in a prospective randomized Phase III study to achieve clinically significant seizure control in TSC patients[1] Seizures are the most…
-
Media ReleaseSandoz receives EC approval for subcutaneous route of administration in biosimilar Binocrit's® nephrology indicationSandoz' epoetin alfa product offering has already generated more than 400,000[1] patient years of experience worldwide EC approval expands Sandoz biosimilar offering to the healthcare community…
-
Media ReleaseNovartis receives EU approval for Revolade® as first-in-class therapy for children aged 1 year and above with chronic ITPEU approval of Revolade expands treatment options for pediatric patients aged 1 year and above with chronic ITP who have not responded to other therapies Two formulations approved: once-daily…
-
Media ReleaseNew analyses show Novartis' Entresto(TM) reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless...New analyses show Novartis' Entresto(TM) reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless of prior heart…
March 2016
-
Media ReleaseNovartis publishes updated 2015 segment financials reflecting new division structureUpdated segment financials reflect transfer of Ophthalmic Pharmaceuticals franchise from Alcon to Pharmaceuticals, and 19 mature products from Pharmaceuticals to Sandoz, as outlined in Q4 and FY…
-
Media ReleaseNovartis' Cosentyx superior to Stelara in delivering long-lasting skin clearance (PASI 90) for psoriasis patients at 52 weeksNew data at AAD 2016 shows Cosentyx® is significantly more efficacious than Stelara in sustaining skin clearance (PASI 90 to PASI 100) at 52 weeks[1] Cosentyx delivered and sustained skin…
February 2016
-
Media ReleaseFDA approves new indication for Novartis drug Afinitor® for progressive, nonfunctional GI and lung neuroendocrine tumors (NET)In advanced progressive, nonfunctional NET, Afinitor is the first approved treatment for patients with lung NET and the first oral therapy for GI NET Approval helps fulfill unmet need as…
-
Media ReleaseNovartis shareholders approve all resolutions proposed by Board of DirectorsShareholders approve 19th consecutive dividend increase to CHF 2.70 (+4%) per share for 2015 Dr. Joerg Reinhardt confirmed by shareholders as Chairman of the Novartis Board of Directors as well as…
Pagination
- ‹ Previous page
- 1
- …
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- …
- 100
- › Next page